» Articles » PMID: 35873020

SQSTM1/p62 Regulate Breast Cancer Progression and Metastasis by Inducing Cell Cycle Arrest and Regulating Immune Cell Infiltration

Overview
Journal Genes Dis
Date 2022 Jul 25
PMID 35873020
Authors
Affiliations
Soon will be listed here.
Abstract

The autophagy adaptor protein SQSTM1/p62 is overexpressed in breast cancer and has been identified as a metastasis-related protein. However, the mechanism by which SQSTM1/p62 contributes to breast cancer progression and tumor microenvironment remains unclear. This study revealed that silencing expression suppressed breast cancer progression via regulating cell proliferation and reshaping the tumor microenvironment (TME). Here, we found that SQSTM1/62 was overexpressed in multiple human cancer tissue types and that was correlated with poor patient overall survival (OS) and disease-free survival (DFS). Moreover, we found that short-hairpin RNA (shRNA)-mediated knockdown of expression significantly inhibited cell proliferation, migration, and invasion, and promoted cell death , as well as suppressed breast cancer growth and lung metastasis . In addition, flow cytometry analysis of splenocytes and tumor infiltrating lymphocytes (TILs) indicated that the numbers of CD8α interferon (IFN)-γ cells (CTLs) and CD4IFN-γ (Th1) cells were increased while those of CD4IL-4 (Th2) cells, tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) were decreased. RT-PCR analyses showed that the gene expression of Th1/Th2 cytokines changed in the tumor microenvironment. Silencing /62 suppressed tumor cell lung metastasis. Together, our results provide strong evidence that silencing tumor cell /62 inhibited tumor growth and metastasis through cell cycle arrest and TME regulation. This finding provides a novel molecular therapeutic strategy for breast cancer progression and metastasis treatment.

Citing Articles

Recent advances in the role of high-salt diet in anti- and pro-cancer progression.

Tang S, Xu J, Wan P, Jin S, Zhang Y, Xun L Front Immunol. 2025; 16:1542157.

PMID: 39944693 PMC: 11814453. DOI: 10.3389/fimmu.2025.1542157.


Chronic IL-1-Exposed LNCaP Cells Evolve High Basal p62-KEAP1 Complex Accumulation and NRF2/KEAP1-Dependent and -Independent Hypersensitive Nutrient Deprivation Response.

Dahl-Wilkie H, Gomez J, Kelley A, Manjit K, Mansoor B, Kanumuri P Cells. 2025; 14(3).

PMID: 39936983 PMC: 11816438. DOI: 10.3390/cells14030192.


The combined signatures of programmed cell death and immune landscape provide a prognostic and therapeutic biomarker in the hepatocellular carcinoma.

Liu W, Huang Y, Xu Y, Gao X, Zhao Y, Fan S Front Chem. 2024; 12:1484310.

PMID: 39600313 PMC: 11591233. DOI: 10.3389/fchem.2024.1484310.


Current state of research on copper complexes in the treatment of breast cancer.

Hu K, Guo J, Zeng J, Shao Y, Wu B, Mo J Open Life Sci. 2024; 19(1):20220840.

PMID: 38585632 PMC: 10997149. DOI: 10.1515/biol-2022-0840.


Elevated aerobic glycolysis driven by p62-mTOR axis promotes arsenic-induced oncogenic phenotypes in human mammary epithelial cells.

Li Y, Liu J, Yao D, Guo Z, Jiang X, Zhang C Arch Toxicol. 2024; 98(5):1369-1381.

PMID: 38485781 DOI: 10.1007/s00204-024-03709-2.


References
1.
Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A . Th9 Cells Represent a Unique Subset of CD4 T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell. 2018; 33(6):1048-1060.e7. PMC: 6072282. DOI: 10.1016/j.ccell.2018.05.004. View

2.
New J, Arnold L, Ananth M, Alvi S, Thornton M, Werner L . Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res. 2017; 77(23):6679-6691. PMC: 5712244. DOI: 10.1158/0008-5472.CAN-17-1077. View

3.
Katheder N, Khezri R, OFarrell F, Schultz S, Jain A, Rahman M . Microenvironmental autophagy promotes tumour growth. Nature. 2017; 541(7637):417-420. PMC: 5612666. DOI: 10.1038/nature20815. View

4.
Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K . p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016; 7:12030. PMC: 4931237. DOI: 10.1038/ncomms12030. View

5.
Moscat J, Karin M, Diaz-Meco M . p62 in Cancer: Signaling Adaptor Beyond Autophagy. Cell. 2016; 167(3):606-609. PMC: 5114003. DOI: 10.1016/j.cell.2016.09.030. View